Further, some studies showed immune checkpoint inhibitors have poor efficacy in NSCLC patients who harbor an EGFR mutation or ALK translocation, whereas they appear to be active in those with a BRAF mutation (21, 22). This evidence concerns the gene EGFR and non-small cell lung carcinoma.